Astal Laboratories Ltd

Astal Lab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Astal Laboratories Ltd

₹ 78.1 0.79%
24 Jun 4:01 p.m.
astallabs.com BSE: 512600
About

Astal Laboratories Ltd is engaged in Manufacturing and Trading of all kinds of active Pharmaceutical Ingredients (Bulk Drugs).[1]

Key Points

Business Update[1]
Astal Laboratories Limited (formerly Macro International Limited) was taken over in 2022 under SEBI takeover regulations, following which its objects were changed to manufacturing and sale of pharmaceutical intermediates and bulk drugs. The name was subsequently changed to Astal Laboratories Limited in May 2024.

Website BSE
  • Market Cap ₹ 342 Cr.
  • Current Price ₹ 78.1
  • High / Low ₹ 103 / 60.4
  • Stock P/E 42.1
  • Book Value ₹ 77.5
  • Dividend Yield 0.00 %
  • ROCE 6.31 %
  • ROE 4.47 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Stock is trading at 1.01 times its book value
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 282% CAGR over last 5 years
  • Company's working capital requirements have reduced from 96.3 days to 73.6 days

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding is low: 4.53%
  • Company has a low return on equity of 7.91% over last 3 years.
  • Company has high debtors of 169 days.
  • Promoter holding has decreased over last 3 years: -63.6%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
3.43 1.36 12.25 8.41 12.25 13.15 13.16 14.46 23.47 25.33 37.52 52.24 40.92
3.40 1.36 11.67 7.92 11.67 10.77 10.27 11.14 19.29 22.18 33.65 48.69 38.73
Operating Profit 0.03 0.00 0.58 0.49 0.58 2.38 2.89 3.32 4.18 3.15 3.87 3.55 2.19
OPM % 0.87% 0.00% 4.73% 5.83% 4.73% 18.10% 21.96% 22.96% 17.81% 12.44% 10.31% 6.80% 5.35%
0.09 0.01 0.00 0.00 0.00 0.03 0.00 0.06 0.04 0.06 0.03 0.04 0.07
Interest 0.00 0.00 0.00 0.00 0.00 0.06 0.09 0.28 0.27 0.30 0.31 0.33 0.47
Depreciation 0.00 0.00 0.02 0.01 0.02 0.01 0.03 0.08 0.10 0.12 0.12 0.12 0.32
Profit before tax 0.12 0.01 0.56 0.48 0.56 2.34 2.77 3.02 3.85 2.79 3.47 3.14 1.47
Tax % 16.67% 0.00% 0.00% 0.00% 0.00% 27.78% 27.80% 17.55% 28.57% 25.45% 25.36% 24.52% 26.53%
0.10 0.01 0.56 0.49 0.56 1.69 2.00 2.49 2.74 2.09 2.58 2.36 1.09
EPS in Rs 0.25 0.03 1.41 1.00 0.57 1.72 2.03 2.53 2.79 2.13 2.40 2.19 0.26
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 0 0 0 0 0 0 0 3 24 64 156
0 0 0 0 0 0 0 0 4 23 51 143
Operating Profit -0 -0 -0 -0 -0 -0 0 -0 -0 1 13 13
OPM % 10% -4% 5% 20% 8%
0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 1 1
Depreciation 0 0 0 0 0 0 0 0 0 0 0 1
Profit before tax 0 0 0 0 -0 -0 0 -0 0 1 12 11
Tax % -260% 50% 0% 12% 0% 0% 67% 28% 25% 25%
0 0 0 -0 -0 -0 0 -0 0 1 9 8
EPS in Rs 0.45 0.03 0.03 -0.03 -0.20 -0.08 0.03 -0.05 0.05 0.79 9.08 1.92
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 279%
3 Years: 257%
TTM: 143%
Compounded Profit Growth
10 Years: 82%
5 Years: 282%
3 Years: 640%
TTM: -9%
Stock Price CAGR
10 Years: %
5 Years: 55%
3 Years: 39%
1 Year: -1%
Return on Equity
10 Years: 7%
5 Years: 8%
3 Years: 8%
Last Year: 4%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 4 4 4 4 4 4 4 4 4 10 10 42
Reserves 1 1 1 1 1 1 1 1 1 13 26 285
0 0 0 0 0 0 0 0 0 0 13 13
0 0 0 0 0 0 0 0 5 13 14 60
Total Liabilities 5 5 5 5 5 5 5 5 10 37 63 400
0 0 0 0 0 0 0 0 0 1 11 12
CWIP 0 0 0 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 0 0 0 277
5 5 5 5 5 5 5 5 10 36 52 110
Total Assets 5 5 5 5 5 5 5 5 10 37 63 400

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-0 -0 -0 -0 -0 -0 -0 -0 -1 -6 -13 -3
0 0 0 0 0 0 0 0 2 -6 -8 -1
0 0 0 0 0 0 0 0 0 18 3 5
Net Cash Flow -0 0 0 0 0 0 0 -0 0 6 -17 0
Free Cash Flow -0 -0 -0 -0 -0 -0 -0 -0 -1 -11 -18 -3
CFO/OP 170% 81% 104% 100% 81% 95% -950% 125% 1,021% -496% -96% -16%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 0 337 244 157 169
Inventory Days 0 18 112 76
Days Payable 197 82 142
Cash Conversion Cycle 0 337 65 187 103
Working Capital Days -73 138 118 97 74
ROCE % 1% 1% 0% 0% -2% -1% 0% 0% 1% 8% 35% 6%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Revenue from Interest Income (Financial/Lending Business phase)
₹ Lacs

Log in to view insights

Please log in to see hidden values.

Login
Number of Owned Pharmaceutical Plants
Number
Number of Permanent Employees
Number
Reliance on Third-Party Manufacturing
Binary (1=Yes, 0=No)

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026May 2026
55.72% 39.79% 19.93% 19.93% 19.93% 19.93% 19.93% 19.93% 18.19% 18.19% 4.70% 4.53%
44.28% 60.21% 80.07% 80.07% 80.07% 80.07% 80.07% 80.08% 81.81% 81.79% 95.29% 95.48%
No. of Shareholders 1,1691,1851,2411,2421,6291,9252,3022,7212,8992,9263,0653,314

Documents

Announcements

Annual reports